“…Further assessment of eligibility, based on the study of the full-text papers, led to the exclusion of 83 papers. Finally, 27 studies involving 252 patients were included in the final analysis ( Figure 1 ) [ 1 , 2 , 7 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 ]. Of these, 19 studies involved only patients with synchronous cancers, 5 studies involved only metachronous PCa patients, and 3 studies involved mixed populations.…”